Comment on: Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 1050-1051

  Sendi, Parham ^a,b,c   Zimmerli, Werner ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bone infections; GBS; Group B Streptococcus; Infectious diseases; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; PENICILLIN BINDING PROTEIN; PENICILLIN G;

BACTERIUM ISOLATE; BIOFILM; BONE AND JOINT INFECTIONS; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG EFFICACY; DRUG HALF LIFE; HIP PROSTHESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIGAND BINDING; NONHUMAN; OUTCOME ASSESSMENT; PROSTHESIS INFECTION; PROSTHETIC JOINT INFECTION; PROTEIN BINDING; RELAPSE; STREPTOCOCCUS AGALACTIAE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEFTRIAXONE; FEMALE; HUMANS; PENICILLIN G; PROSTHESIS-RELATED INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84858635343     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr583     Document Type: Letter

References (10)

1. Gaudreau C, Lecours R, Ismaïl J et al. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother 2010; 65: 594-5.
2. Longtin J, Vermeiren C, Shahinas D et al. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy. Antimicrob Agents Chemother 2011; 55: 2983-5.
3. Sendi P, Christensson B, Uçkay I et al. Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect 2011; 79: 64-9.
4. EUCAST. MIC Distributions. http://217.70.33.99/Eucast2/SearchController/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=-1&Specium=163 (14 December 2011, date last accessed).
5. Bamberger DM, Foxworth JW, Bridwell DL et al. Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005; 719-814.
6. Landersdorfer CB, Bulitta JB, Kinzig M et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48: 89-124.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
8. Olson ME, Ceri H, Morck DW et al. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66: 86-92.
9. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
10. Pavoni GL, Giannella M, Falcone M et al. Conservative medical therapy of prosthetic joint infections: retrospective analysis of an 8-year experience. Clin Microbiol Infect 2004; 10: 831-7.